跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TASIGNA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TASIGNA
Authorized
STANDARD
TASIGNA
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
eb03fa73e79c54f9
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
eb03fa73e79c54f9
Drug Approval Canada Name
TASIGNA
Product Name
TASIGNA
Status
Cancelled Post Market
Status Date
2023-10-04
Original Market Date
2019-05-17
Din
02481715
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EA03 NILOTINIB
Atc Name
l 01 ea 03
Aig Number
0152484003
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
NILOTINIB (NILOTINIB HYDROCHLORIDE MONOHYDRATE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
eb03fa73e79c54f9
Type
Standard
Back to Health Canada Approvals